On the other hand, in clinical trials, the combination of EGFR TKIs with PD-1/PD-L1 inhibitors did not demonstrate a favorable clinical efficacy in patients with EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.